Navigation Links
Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
Date:10/16/2007

">http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy, safety and tolerability of XL784 and the timing of the submission of XL784 data to GSK. Words such as "may," "will," "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the results of any failure of XL784 to demonstrate safety and efficacy in clinical testing, risks related to Exelixis' arrangement with SEI and Exelixis' dependence on and relationship with GSK. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and Exelixis' other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  KIYATEC announced today ... Small Business Innovation Research (SBIR) Phase II Contract ... the 27 institutes and centers that comprise the ... of the two year award, KIYATEC will expand ... issues at the forefront of cancer therapy strategies: ...
(Date:9/18/2014)... LONDON , September 18, 2014 ... their audience, has updated the incredibly successful Serialisation Countdown ... The interactive PDF, available at pharmaserialisation.com shows ... in which they will be coming into force. ... no longer a matter of "if", but "when" they ...
(Date:9/18/2014)... ARBOR, Mich. , Sept. 18, 2014  A ... Research will allow the University of Michigan to establish ... The Glenn Center for Aging Research at ... evidence that drugs can slow the effects of aging ... unlock mechanisms of aging that can help develop medications ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3
(Date:9/18/2014)... 18, 2014 CD-adapco, the largest privately ... today announced its new partnership with Ben Ainslie Racing. ... simulation tool, STAR-CCM+® in the design of its racing ... in the 35th America’s Cup taking place in 2017. ... America’s Cup is sustainability, the set of restrictive rules ...
(Date:9/18/2014)... drink less sugar, according to a new study from ... enough, the study goes on to say, as all ... healthier at school , The research suggests a parent,s ... a child,s diet. , The study found Vancouver school ... per cent more likely to eat vegetables during the ...
(Date:9/18/2014)... is available in German . ... Mnchen have won the ,International Space Station Research ... As their prize, the scientists will see the International ... The project involves crystallizing two proteins of the hepatitis ... proteins to the International Space Station is scheduled to ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Relias Learning, the ... and human services markets, today announced it has been named ... growing private companies in America. , In the three-year period ... moved up almost 2,000 spots on the Inc. 5000 list ... , “The industries we serve continue to grow, ...
(Date:9/18/2014)... 18, 2014 According to a new market ... Market - Global Industry Analysis, Size, Share, Growth, Trends and ... market was valued at USD 77607.7 million in 2013 and ... 2014 to 2020, to reach an estimated value of USD ... services market is growing at a rapid pace due to ...
Breaking Medicine News(10 mins):Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Kids eat better if their parents went to college 2Health News:Hepatitis C virus proteins in space 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4
... University of Rochester, New York suggests that the activated ... properties,which until now is being used to treat septic ... stroke. Researchers who conducted the study on mice found ... damage associated with ischemic stroke by preventing apoptosis, a ...
... the British Medical Journal has argued that the cause ... stage could be attributed to coloured toilet disinfectants. Researchers ... cancers detected early can be successfully treated and that ... The National programme// for detection of colorectal cancer suggested ...
... A team of doctors from different specialties, recently joined hands ... patients. Dr. Peter Costantino, an otolaryngologist, about three years ago, ... nasal cavity and right eye socket. According to the American ... neck cancer were diagnosed in 2002. This type of cancer ...
... curvature of the spine diagnosed after the age ten, ... to earlier belief that the condition increases mortality rates ... related to the curvature. Researchers from the University of ... with LIS appear to experience only little physical// impairment ...
... associated with good health and parents world over, have ... However, a recent study in New Zealand has raised ... A study involving 20 countries published in the New ... milk containing the A-1 beta case in protein and ...
... Twisthaler has been launched by Schering-Plough as therapy in ... persistent asthma in patients 12 years of age and ... January and is expected to be launched in the ... Asmanex Twisthaler, a dry powder inhaler, contains the orally// ...
Cached Medicine News:
... offer the physician a new approach to supportive ... The weight simply uses gravity to gently close ... or when the eyelid muscle is relaxed. ... variety of skin tone colors to match a ...
... Heidelberg Multi Color (HMC) ... a microprocessor-controlled precision assessment ... the red/green range (Rayleigh ... (Moreland equation) with integrated ...
... VersaSuite practice management software is ... the business and clinical aspects of ... solution offers support for the financial, ... the eye care professional. Designed as ...
... in our country to provide greater and ... recent government regulations require it. The Access ... your wheelchair-bound patients easy and comfortable access ... to leave their wheelchair. , ,The Access ...
Medicine Products: